Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 3/20 | 0.32 |
| ▸ | CES1 | P23141 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11687013 | 0.82 | CES1 (0.38) | CES2CES1ALDH1A1TSHRDAO | |
| SCHEMBL2039663 | 0.81 | CA12 (0.41) | CES2CES1ALDH1A1NAPRTCA12 | |
| SCHEMBL2721515 | 0.81 | TSHR (0.33) | ALDH1A1TSHRPOLBCYP3A4PARP1 | |
| SCHEMBL2294880 | 0.76 | MAPT (0.35) | CES2CES1ALDH1A1TSHRMAPT | |
| SCHEMBL4910226 | 0.76 | TSHR (0.35) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL23581641 | 0.76 | AKT1 (0.35) | ALDH1A1ALOX15CYP3A4MAPTHSD17B10 | |
| SCHEMBL4056278 | 0.76 | ALDH1A1 (0.34) | ALDH1A1RECQL | |
| SCHEMBL9073847 | 0.75 | KDM4E (0.33) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL23581634 | 0.75 | CYP3A4 (0.34) | CA12CA1CA2CA4CA7 | |
| SCHEMBL16862933 | 0.74 | FFAR1 (0.53) | ALDH1A1FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087069-B1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE BV (NL) | 2019-01-30 | — | — | EP | claimed |
| US-9969687-B2 | Compounds useful as CCR9 modulators | NORGINE B.V. (NL) | 2018-05-15 | — | — | US | claimed |
| US-20170001959-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | claimed |
| EP-3087069-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | Norgine BV (NL) | 2016-11-02 | — | — | EP | claimed |
| WO-2015097121-A9 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2015-09-03 | — | — | WO | claimed |
| WO-2015097121-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2015-07-02 | — | — | WO | claimed |
| EP-3087069-B1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE BV (NL) | 2019-01-30 | — | — | EP | disclosed |
| US-9969687-B2 | Compounds useful as CCR9 modulators | NORGINE B.V. (NL) | 2018-05-15 | — | — | US | disclosed |
| US-20170001959-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| EP-3087069-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | Norgine BV (NL) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015097121-A9 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015097121-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | NORGINE B.V. (NL) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015003723-A1 | SUBSTITUTED 4-PROLINE DERIVATIVES AS IGLUR ANTAGONISTS | Københavns Universitet (DK) | 2015-01-15 | — | — | WO | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| EP-1811844-A1 | METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER | Minerva Biotechnologies Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007053135-A1 | METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001959-A1 | COMPOUNDS USEFUL AS CCR9 MODULATORS | CCR9, CCR1, CCR10 | SRC 3425/4885CES2 1763/4885CES1 1018/4885 |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MUC1, CD44, TP53 | SRC 894/4885CES2 3582/4885CES1 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.